Prof. Wen-lin Huang, PhD – We are the World

[Say Goodbye to Insulin Injections? Stem Cell Therapy Brings New Hope for Diabetes Treatment]

Daily injections, medication, dietary restrictions We understand your struggles-

High blood sugar not only steals health but also robs life of freedom and joy.

Keynote Speaker: Professor Huang Wenlin

Academician of the European Academy of Sciences | Recipient of the State Council Special Allowance.
Lead Developer of China’s First Phase III Gene Therapy Drug.
Founder of Da Bo Biotechnology.

Major Breakthrough: Led by Professor Huang Wenlin, lead developer of China’s first gene therapy drug, the team introduces.
[Human Umbilical Cord Mesenchymal Stem Cell Injection (E101)], offering new possibilities for curing diabetes!
First Global Opportunity: Free on-site consultations available. Eligible candidates may qualify for complimentary treatment!

Four Major Technological Breakthroughs:

Safe Sourcing: Sourced from newborn umbilical cords, free from ethical concerns.
No Matching Required: “Off-the-shelf” formulation, ready for immediate use.
Triple Repair Mechanism: Repairs pancreatic ẞ-cells + improves insulin resistance + reduces complications.
Clinically Validated: Shows significant blood glucose reduction trends with excellent safety profile

Clinical Progress:

Phase I trials have commenced at the Diabetes Center of The First Affiliated Hospital of Sun Yat-sen University.
Free treatment slots are now open for type 2 diabetes patients!.

Who Should Attend?

Diabetes patients and their families.
Endocrinology healthcare professionals and researchers.
Biopharmaceutical companies and investment institutions.
Those interested in regenerative medicine.

Event Details:

Theme: Current Status and Future of Stem Cell Therapy for Diabetes.
Date: November 9 and November 11, 2025, 14:30-16:30.
Format: Expert presentations + case studies + on-site consultations.

New Hope for Diabetes Patients

E101 Technology Highlights

Safe Source: Sourced from neonatal umbilical cords, ethically non-controversial, and renewable.
No Matching Required: “Off-the-shelf” preparation, ready for immediate use.
Triple Mechanism: Repairs pancreatic ẞ-cells + improves insulin resistance + reduces complications.
Preliminary clinical data show significant glucose-lowering trends, excellent anti-inflammatory effects, and a strong safety profile.

Clinical Progress and Participation Opportunities

Phase I clinical trials have successfully commenced at the Diabetes Center of The First Affiliated Hospital of Sun Yat-sen University.
A limited number of free treatment slots are now open for type 2 diabetes patients-applications are welcome.

Event Information

Target Audience

Diabetes patients and their families.
Endocrinologists, researchers, and medical students.
Biopharmaceutical companies and investment representatives.
Professionals interested in regenerative medicine and health innovation.

Agenda

Keynote Speech: Prof. Huang Wenlin on “Current Status and Future of Stem Cell Therapy for Diabetes”.
Clinical Case Sharing and Treatment Pathway Consultation.
Live Q&A and Collaboration Session.
Time: November 9, 2025, 2:30 PM -4:30 PM/

Our Promise:

This is not a fantasy-it’s science.
Regain your dietary freedom and restart a vibrant life!

Register now for a chance to receive complimentary treatment:

Add Your Heading Text Here

(Note: Treatment eligibility subject to clinical trial protocols and medical evaluation)

Operated by: Da Bo Biotechnology

A groundbreaking project based on clinical research breakthroughs